The future of the unknown Hai Xin shares 10 "burn money" project still loss

Outside the environment (300272.SZ) actively expand into the immune cell storage project, its city-listed companies Haixin shares (600851.SH) in fact has long been involved. As of July 9 closed, open the total market value of environmental protection reached 5.336 billion yuan, and the pioneer Haixin shares of the total market value of only 5.3 billion yuan. As of now, Hai Xin, a subsidiary of Hai Hin Biotechnology and the second military Medical University of Shanghai, developed the "antigen-sensitized human dendritic cells" (APDC), the first self-developed and CFDA approved by China, for the treatment of advanced colorectal cancer vaccine, by the Chinese Academy of Engineering Cao Shetao, the main idea is " The use of chemotherapy to remove some immunosuppressive factors, the use of antigen-sensitized dendritic cells to stimulate tumor-specific immunity. The project development team is quite strong, Cao Shetao is now the dean of the Chinese Academy of Medical Sciences, director of the China Institute of Immunology, President of the National 973 Immunological program, the team on "dendritic cells," a new study published online in the April 18 issue of science. According to industry insiders, cancer treatment with antigen-sensitized human dendritic cells (APDC) is targeted at advanced cancer treatment development of a new generation of therapeutic tumor vaccines. Dendritic cell (DC) is the strongest antigen-presenting cell in vivo, and is the initiator of immune system, which is in the center of initiating, regulating and sustaining immune response. The use of dendritic cells loaded with tumor antigens as tumor seedlings can effectively break the body's tolerance to tumors, activate T lymphocytes, kill and remove tumor cells. It is understood that "antigen-sensitized human dendritic cells" (APDC) is one of the country's 863 projects, completed preclinical studies in 2001, a clinical trial began in April 2002. The haixin creature introduced APDC in the hands of Shanghai's second military Medical university and acquired intellectual property rights before and after 2004. At present, Hai Hin Biology has at least 6 research projects, corresponding to hepatitis B, AIDS and cancer treatment, including APDC, 1L-1S-TC fusion protein, recombinant adenovirus vaccine. APDC two clinical effect, effective rate of 49%. The research and Development project was approved by the state Food and Drug Administration at the end of July 2012 and agreed to carry out the Ⅲ period clinical trial. However, the long process of research and development of new drugs has not been able to bring benefits to the listed companies. Haixin investment platform Hai Hin Asset Management company has been losing money since 2009, with a loss of 133,500 yuan to 3.1257 million yuan in 2011. Research and development for 10 years has not seen the benefits of continuing to "burn money." June 2013, Hai Xin shares to the sea-Yan biological loan 20 million yuan, used to start APDC Project Ⅲ phase clinical trial. Haixin shares have announced that, according to the current development of the APDC Project Ⅲ phase of clinical trial program, the Ⅲ phase of the clinical trial is expected to be more than three years, the test results are also uncertain. At present, in Beijing, Shanghai, Zhejiang and other place initially selected 20 hospitals as clinical research units, and established a "Data management system for cell treatment products. Recently, Hai Xin shares dong Helili in the media interview, said that the current APDC of the Ⅲ phase of clinical trials have not started, currently under construction for vaccine preparation clinical trial base, after the construction of the base can start to do clinical. In addition, because it is trans-line investment in medicine, the company's management of the APDC project more cautious, may be slow progress. Pharmaceutical industry researcher Fu Hao told reporters, whether the background strength, or research and development progress, Haixin shares are in the industry leading.